Search

Displaying results 1501 - 1510 of 3735 in total
  1. Drug

    Agalsidase beta

    go.drugbank.com/drugs/DB00103
    ApprovedInvestigational

    Agalsidase beta is a recombinant human α-galactosidase A similar to agalsidase alfa. While patients generally do not experience a clinically significant difference in outcomes between the two drugs, some patients may experience greater b...

  2. Drug

    Cintredekin besudotox

    go.drugbank.com/drugs/DB05305
    Investigational

    Cintredekin besudotox is made from a human protein, Interleukin 13 (IL13), linked to a bacterial toxin, _Pseudomonas exotoxin_ (PE). The IL13 portion binds to receptors on the tumor.

  3. Drug

    PF-04447943

    go.drugbank.com/drugs/DB11953
    Investigational

    PF-04447943 has been investigated for the treatment of Alzheimer's Disease.

  4. Drug

    PF-00446687

    go.drugbank.com/drugs/DB12517
    Investigational

    PF-00446687 has been investigated for the treatment of Erectile Dysfunction.

    Categories: Receptor, Melanocortin, Type 4, agonists
  5. Drug

    PD-98059

    go.drugbank.com/drugs/DB17042
    Experimental

    PD-98059 is an inhibitor of MAP-kinase kinase activation.[A253072]

  6. Drug

    DPDPE

    go.drugbank.com/drugs/DB08861
    Experimental

    A heterodetic cyclic peptide that is a cyclic enkephalin analogue, having D-penicillaminyl residues located at positions 2 and 5, which form the heterocycle via a disulfide bond.

  7. Drug

    Tofacitinib

    go.drugbank.com/drugs/DB08895
    ApprovedInvestigational

    Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid a...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  8. Drug

    Reteplase

    go.drugbank.com/drugs/DB00015
    ApprovedInvestigationalWithdrawn

    Human tissue plasminogen activator, purified, glycosylated, 355 residues purified from CHO cells. Retavase is considered a "third-generation" thrombolytic agent, genetically engineered to retain and delete certain portions of human tPA. ...

    Synonyms: Human t-PA (residues 1-3 and 176-527)
  9. Drug

    PD-169316

    go.drugbank.com/drugs/DB17040
    Experimental

    PD-169316 is a p38 MAP kinase inhibitor.[A253062]

  10. Drug

    PD-173952

    go.drugbank.com/drugs/DB17041
    Experimental

    PD-173952 is a potent Myt1 kinase inhibitor.[A253067]